Browse

Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer

Cited 118 time in Web of Science Cited 138 time in Scopus
Authors
Han, S-W; Oh, D-Y; Im, S-A; Park, S R; Lee, K-W; Song, H S; Lee, N-S; Lee, K H; Choi, I S; Lee, M H; Kim, M A; Kim, W H; Bang, Y-J; Kim, T-Y
Issue Date
2009-01-08
Publisher
Nature Publishing Group
Citation
Br J Cancer. 2009 Jan 27;100(2):298-304. Epub 2009 Jan 6.
Keywords
AdultAgedAntibodies, Monoclonal/administration & dosageAntineoplastic Combined Chemotherapy Protocols/*therapeutic useFemaleFluorouracil/administration & dosageHumansLeucovorin/administration & dosageLiver Neoplasms/chemistry/*drug therapy/secondaryMaleMiddle AgedNeoplasm Recurrence, Local/diagnosis/drug therapyNeoplasm StagingOrganoplatinum Compounds/administration & dosagePeritoneal Neoplasms/chemistry/*drug therapy/secondaryPrognosisProspective StudiesStomach Neoplasms/chemistry/*drug therapy/pathologySurvival RateTreatment OutcomeTumor Markers, Biological/*analysis
Abstract
This prospective study was conducted with the Korean Cancer Study Group to evaluate the efficacy and safety of cetuximab combined with modified FOLFOX6 (mFOLFOX6) as first-line treatment in recurrent or metastatic gastric cancer and to identify potential predictive biomarkers. Patients received cetuximab 400 mg m(-2) at week 1 and 250 mg m(-2) weekly thereafter until disease progression. Oxaliplatin (100 mg m(-2)) and leucovorin (100 mg m(-2)) were administered as a 2-h infusion followed by a 46-h continuous infusion of 5-fluorouracil (2400 mg m(-2)) every 2 weeks for a maximum of 12 cycles. Biomarkers potentially associated with efficacy were analysed. Among 38 evaluable patients, confirmed response rate (RR) was 50.0% (95% CI 34.1-65.9). Median time-to-progression (TTP) was 5.5 months (95% CI 4.5-6.5) and overall survival (OS) 9.9 months. Eleven patients having tumour EGFR expression by immunohistochemistry with low serum EGF and TGF-alpha levels showed a 100% RR compared to 37.0% in the remaining 27 patients (P<0.001). Moreover, ligand level increased when disease progressed in seven out of eight patients with EGFR expression and low baseline ligand level. No patient exhibited EGFR amplification or K-ras mutations. Gastric cancer patients with EGFR expression and low ligand levels had better outcomes with cetuximab/mFOLFOX6 treatment.
ISSN
1532-1827 (Electronic)
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19127259

http://www.nature.com/bjc/journal/v100/n2/pdf/6604861a.pdf

http://hdl.handle.net/10371/46307
DOI
https://doi.org/10.1038/sj.bjc.6604861
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse